Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux | Aplastic Anemia & MDS International Foundation Return to top.

Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux

Journal Title: 
Leuk Res.
Primary Author: 
Cheng KL
Author(s): 
Cheng KL, Brody J, Warshall CE, Sloand EM, Allen SL
Original Publication Date: 
Thursday, April 1, 2010

No abstract available.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
  • paroxysmal nocturnal hemoglobinuria (PNH)
Share with addtoany.com.